In addition to the mesenchymal state and EGFR-mutant tumor cells mentioned above, EGFR-TKI-resistant LUAD cells also increase cellular sensitivity to ferroptosis, and the histone deacetylase inhibitor Vorinostat can further downregulate the expression of xCT in EGFR mutant LUAD cells and enhance the effect of ferroptosis induction therapy [50]. This evidence concerns the gene EGFR and neoplasm.